A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)

Last updated: July 7, 2025
Sponsor: Equilibra Bioscience LLC
Overall Status: Active - Recruiting

Phase

1

Condition

Hemophilia

Treatment

Placebo

SR604

Clinical Study ID

NCT06349473
SR604-1
  • Ages 18-60
  • Male
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

Part A:

  • Body mass index between 18 and 30 kilograms per meter square (kg/m^2), inclusive,and weighs greater than or equal to (>=) 50 kilograms (kg), less than or equal to (<=) 90 kg.

  • No clinically significant findings on medical examination, including physicalexamination, 12-lead electrocardiogram, and clinical laboratory tests.

  • Sexually active men must commit to use an effective method of birth control whiletaking the study intervention and for 90 days after the dose of study intervention.

Part B:

  • Participants must have one of the following bleeding disorders: Severe congenitalHemophilia A and Severe and/or moderately severe congenital Hemophilia B.

  • Participants whose bleeding is not well controlled on their current treatmentregimen.

  • Medical records documenting a minimum of 2 years of bleeding event history.

  • Willing to undergo a weaning period from prior Hemophilia A or Hemophilia Btreatment or prophylaxis.

  • Sexually active men must commit to use an effective method of birth control whiletaking the study intervention and for 90 days after the dose of study intervention.

Exclusion

Key Exclusion Criteria:

Part A:

  • Participant has clinically significant history or evidence of cardiovascular,respiratory (including all chronic lung diseases), hepatic, renal, gastrointestinal,endocrine, neurological, immunological, bleeding, or psychiatric disorder(s).

  • Participant has a mean pulse less than (<) 40 or greater than (>) 90 beats perminute (bpm), mean systolic blod pressure (BP) < 90 millimeter of mercury (mmHg) or > 140 mmHg, or mean diastolic BP < 50 mmHg or > 90 mmHg at the screening visit.

  • Participant has a mean corrected QT corrected for heart rate by Fridericia's formula (QTcF) of > 450 msec at the Screening Visit.

  • Participant has had injury, trauma, and/or major surgery within 3 months beforeScreening, or is planned to undergo surgery during the study.

  • Participant has received vaccination within 14 days before the dose of studyintervention or has a vaccination planned during the study.

  • History of one or more of the following in participants and/or family members:

  1. Factor V (FV) Leiden mutation.

  2. Activated protein C (APC) resistant.

  3. Protein C (PC) or protein S (PS) deficiency.

  4. Prothrombin 20210 mutation;

  5. Antithrombin III (ATIII) deficiency.

  • History of clinically significant intracranial hemorrhage, pneumonia, chronic liverdisease, liver or kidney transplants, or malignant diseases.

  • Any medical condition (eg, diabetes, obesity.) which, in the Investigator's opinion,could compromise participant safety, interfere with study intervention metabolism,or put the study outcome at undue risk. Any condition for which, in the opinion ofthe Investigator, participation would not be in the best interest of the participantor could prevent, limit or confound protocol-specified assessments.

  • Participants with a history of all types of thrombosis, including any arterialand/or venous thrombosis, superficial thrombophlebitis, or embolism. Additionally,participants with a history of thrombotic microangiopathy, stroke, and transientischemic attack (TIA), or abnormal findings in any prior laboratory thrombophiliaevaluation will be excluded.

Part B:

  • Participants with a history of all types of thrombosis, including any arterialand/or venous thrombosis, superficial thrombophlebitis, or embolism. Additionally,participants with a history of thrombotic microangiopathy, stroke, and TIA, orabnormal findings in any prior laboratory thrombophilia evaluation will be excluded.

  • History of one or more of the following in participants and/or family members:

  1. FV Leiden mutation.

  2. APC resistant.

  3. PC or PS deficiency.

  4. Prothrombin 20210 mutation.

  5. ATIII deficiency.

  • Impaired cardiac function or clinically significant cardiac disease, including anyof the following:
  1. Clinically significant and/or uncontrolled heart disease such as congestiveheart failure requiring treatment (New York Heart Association Grade >=2), leftventricular ejection fraction < 50% as determined by multiple gated acquisitionor echocardiogram, or clinically significant arrhythmia.

  2. QTcF > 450 ms ECG or congenital Long QT Syndrome at the Screening Visit.

  3. Acute myocardial infarction or unstable angina pectoris < 3 months prior tostudy entry.

  • Uncontrolled hypertension (systolic BP > 150 mmHg and diastolic BP > 100 mmHg), ahistory of hypertension crisis, or a history of hypertensive encephalopathy.

  • Participant with the following laboratory abnormalities:

  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 ×upper limit of normal (ULN);

  2. Total bilirubin ˃3.0 × ULN and direct bilirubin ˃1.5 × ULN (unless due toGilbert's syndrome).

  • Calculated creatinine clearance ˂ 60 mL/min using the 2021 Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) formula at the Screening Visit.

  • Participant has positive test result for human immunodeficiency virus (HIV)antibody. a) If participants test positive for hepatitis B core antibody (HBcAb),additional tests including hepatitis B surface antibody, hepatitis B surface antigen (HBsAg), and hepatitis B viral deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) will be conducted to determine if there is an active infection. Participantswith active infection will be excluded from the study.; b) Participants who testpositive for hepatitis C virus antibody will be required to have a negative resultfor hepatitis C viral ribonucleic acid (RNA) PCR before enrollment. Individuals withpositive results for hepatitis C PCR will be excluded from the study.

  • Chronic liver disease (Child-Pugh class C hepatic impairment), or history of liveror kidney transplants.

  • Injury, trauma, and/or major surgery (mediastinoscopy, insertion of a central venousaccess device, and insertion of a feeding tube are not considered major surgery),major dental procedures (extractions, etc.) within 4 weeks of the first dose ofSR604 or planned surgery during the study.

  • Active infection requiring systemic antibiotic or antiviral therapy or in a sepsiscondition within 14 days prior to the first dose of SR604.

  • Any medical condition (eg, diabetes, obesity) which, in the Investigator's opinion,could compromise participant safety, interfere with SR604 metabolism, or put thestudy outcome at undue risk.

Study Design

Total Participants: 36
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
May 10, 2024
Estimated Completion Date:
April 27, 2026

Study Description

This is a first-in-human (FIH) study to be conducted with SR604. The study will enroll healthy participants (Part A) and participants with Hemophilia A or Hemophilia B (Part B).

In Part A (single ascending dose [SAD]): Healthy participants will be randomized in a 2:1 ratio in each of the 3 to 4 (Cohort 4 is optional) sequential cohorts. All cohorts will include participants receiving active treatment with SR604 and the other participant receiving matching placebo.

In Part B (multiple ascending dose [MAD]): Participants with Hemophilia A or Hemophilia B, with or without inhibitors, will be enrolled in 4 cohorts with four dose levels and is planned to receive SR604 subcutaneously.

The overall duration of study participation will be approximately 3 months.

Connect with a study center

  • McMaster University Medical Centre, Hamilton Health Sciences

    Hamilton, Ontario L8N 3Z5
    Canada

    Site Not Available

  • California Clinical Trials Medical Group (CCTMG)

    Glendale, California 91206
    United States

    Completed

  • Children's Hospital Los Angeles

    Los Angeles, California 90027
    United States

    Site Not Available

  • Rush University Medical Center

    Chicago, Illinois 60612
    United States

    Site Not Available

  • LA Center for Bleeding and Clotting Disorders - Metairie

    Metairie, Louisiana 70001
    United States

    Active - Recruiting

  • University of Michigan Hospitals - Michigan Medicine

    Ann Arbor, Michigan 48109
    United States

    Active - Recruiting

  • Washington University School of Medicine

    Saint Louis, Missouri 63110
    United States

    Active - Recruiting

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina 27834
    United States

    Site Not Available

  • Penn State Milton S Hershey Medical Center Pediatrics

    Hershey, Pennsylvania 17033
    United States

    Site Not Available

  • Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.